Alan F. Schatzberg

Clinical Focus

• Psychiatry

Administrative Appointments

• Chair, Stanford University School of Medicine - Psychiatry and Behavioral Sciences , (1991– present )

Professional Education

• Board Certification: Psychiatry, American Board of Psychiatry and Neurology (1975)
• Harvard Medical School (1972) MA
• Massachusetts Mental Health Center (1972) MA
• Lenox Hill Hospital (1969) NY
• New York University School of Medicine (1968) NY

Postdoctoral Advisees

• Amit Etkin, Keith Sudheimer

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. 

• Consulting: Amnestix, Braincells, Cenerx, Corcept therapeutics, Eli lilly, Neuronetics, Pharmaneuroboost, Roche, Xytis
• Royalty Payments: Corcept therapeutics
• Equity: Braincells, Cenerx, Cns response, Corcept therapeutics, Pharmaneuroboost

Research Interests

Biological bases of depressive disorders;, glucocorticoid/dopamine interactions in delusional depression;, pharmacologic treatment of depressive disorders.

Clinical Trials

• Genetics of Symptomatology and Treatment Response in Psychotic Major Depression Recruiting

Publications

• FKBP5 polymorphisms and antidepressant response in geriatric depression. Sarginson JE,  Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM.  Am J Med Genet B Neuropsychiatr Genet.  2009;
• The silver lining of recent effectiveness trials. Schatzberg AF,  World Psychiatry.  2009; 8 (1): 30-2
• Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? Bailey SR,  Harrison CT, Jeffery CJ, Ammerman S, Bryson SW, Killen DT, Robinson TN, Schatzberg AF, Killen JD.  Addict Behav.  2009; 34 (12): 1017-22
• Prefrontal plasticity and stress inoculation-induced resilience. Katz M,  Liu C, Schaer M, Parker KJ, Ottet MC, Epps A, Buckmaster CL, Bammer R, Moseley ME, Schatzberg AF, Eliez S, Lyons DM.  Dev Neurosci.  2009; 31 (4): 293-9
• Extended cognitive behavior therapy for cigarette smoking cessation. Killen JD,  Fortmann SP, Schatzberg AF, Arredondo C, Murphy G, Hayward C, Celio M, Cromp D, Fong D, Pandurangi M.  Addiction.  2008; 103 (8): 1381-90
• The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. Buckley T,  Duggal V, Schatzberg AF.  J Clin Sleep Med.  2008; 4 (3): 235-41
• Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. Schatzberg AF,  Lindley S.  Eur J Pharmacol.  2008; 583 (2-3): 358-64
• The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Buckley TM,  Mullen BC, Schatzberg AF.  Psychoneuroendocrinology.  2007 Sep-Nov; 32 (8-10): 859-64
• Preliminary evidence that hippocampal volumes in monkeys predict stress levels of adrenocorticotropic hormone. Lyons DM,  Parker KJ, Zeitzer JM, Buckmaster CL, Schatzberg AF.  Biol Psychiatry.  2007; 62 (10): 1171-4
• Stress-induced changes in primate prefrontal profiles of gene expression. Karssen AM,  Her S, Li JZ, Patel PD, Meng F, Bunney WE, Jones EG, Watson SJ, Akil H, Myers RM, Schatzberg AF, Lyons DM.  Mol Psychiatry.  2007; 12 (12): 1089-102
• Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Greicius MD,  Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF.  Biol Psychiatry.  2007; 62 (5): 429-37
• Current issues in the classification of psychotic major depression. Keller J,  Schatzberg AF, Maj M.  Schizophr Bull.  2007; 33 (4): 877-85
• Early life stress and novelty seeking behavior in adolescent monkeys. Parker KJ,  Rainwater KL, Buckmaster CL, Schatzberg AF, Lindley SE, Lyons DM.  Psychoneuroendocrinology.  2007; 32 (7): 785-92
• Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Nemeroff CB,  Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephenson H, Schatzberg AF.  Arch Gen Psychiatry.  2007; 64 (4): 466-72
• Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. O'Hara R,  Schröder CM, Mahadevan R, Schatzberg AF, Lindley S, Fox S, Weiner M, Kraemer HC, Noda A, Lin X, Gray HL, Hallmayer JF.  Mol Psychiatry.  2007; 12 (6): 544-55
• Application of microarray technology in primate behavioral neuroscience research. Karssen AM,  Li JZ, Her S, Patel PD, Meng F, Evans SJ, Vawter MP, Tomita H, Choudary PV, Bunney WE, Jones EG, Watson SJ, Akil H, Myers RM, Schatzberg AF, Lyons DM.  Methods.  2006; 38 (3): 227-34
• A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Schatzberg A,  Roose S.  Am J Geriatr Psychiatry.  2006; 14 (4): 361-70
• Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. Schatzberg AF,  Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC.  J Clin Psychiatry.  2006; 67 Suppl 4 27-30
• Clinical and biological effects of mifepristone treatment for psychotic depression. Flores BH,  Kenna H, Keller J, Solvason HB, Schatzberg AF.  Neuropsychopharmacology.  2006; 31 (3): 628-36
• Extended treatment with bupropion SR for cigarette smoking cessation. Killen JD,  Fortmann SP, Murphy GM, Hayward C, Arredondo C, Cromp D, Celio M, Abe L, Wang Y, Schatzberg AF.  J Consult Clin Psychol.  2006; 74 (2): 286-94
• Detecting psychotic major depression using psychiatric rating scales. Keller J,  Gomez RG, Kenna HA, Poesner J, DeBattista C, Flores B, Schatzberg AF.  J Psychiatr Res.  2006; 40 (1): 22-9
• New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. Schatzberg AF,  CNS Spectr.  2006; 11 (12 Suppl 15): 22-7
• Maternal mediation, stress inoculation, and the development of neuroendocrine stress resistance in primates. Parker KJ,  Buckmaster CL, Sundlass K, Schatzberg AF, Lyons DM.  Proc Natl Acad Sci U S A.  2006; 103 (8): 3000-5
• The neuropsychological profile of psychotic major depression and its relation to cortisol. Gomez RG,  Fleming SH, Keller J, Flores B, Kenna H, DeBattista C, Solvason B, Schatzberg AF.  Biol Psychiatry.  2006; 60 (5): 472-8
• Cortisol circadian rhythm alterations in psychotic major depression. Keller J,  Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF.  Biol Psychiatry.  2006; 60 (3): 275-81
• Social stress-related behavior affects hippocampal cell proliferation in mice. Mitra R,  Sundlass K, Parker KJ, Schatzberg AF, Lyons DM.  Physiol Behav.  2006; 89 (2): 123-7
• A randomized trial of the efficacy of group therapy in changing viral load and CD4 counts in individuals living with HIV infection. Belanoff JK,  Sund B, Koopman C, Blasey C, Flamm J, Schatzberg AF, Spiegel D.  Int J Psychiatry Med.  2005; 35 (4): 349-62
• The efficacy of divalproex sodium in the treatment of agitation associated with major depression. Debattista C,  Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF.  J Clin Psychopharmacol.  2005; 25 (5): 476-9
• Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. O'Hara R,  Schröder CM, Kraemer HC, Kryla N, Cao C, Miller E, Schatzberg AF, Yesavage JA, Murphy GM.  Neurology.  2005; 65 (4): 642-4
• The efficacy of antidepressants in the treatment of late-life depression. Roose SP,  Schatzberg AF.  J Clin Psychopharmacol.  2005; 25 (4 Suppl 1): S1-7
• Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Parker KJ,  Buckmaster CL, Schatzberg AF, Lyons DM.  Psychoneuroendocrinology.  2005; 30 (9): 924-9
• Monoamine oxidase and catechol-o-methyltransferase enzyme activity and gene expression in response to sustained glucocorticoids. Lindley SE,  She X, Schatzberg AF.  Psychoneuroendocrinology.  2005; 30 (8): 785-90
• On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. Buckley TM,  Schatzberg AF.  J Clin Endocrinol Metab.  2005; 90 (5): 3106-14
• Mild early life stress enhances prefrontal-dependent response inhibition in monkeys. Parker KJ,  Buckmaster CL, Justus KR, Schatzberg AF, Lyons DM.  Biol Psychiatry.  2005; 57 (8): 848-55
• Mutations in squirrel monkey glucocorticoid receptor impair nuclear translocation. Her S,  Patel PD, Schatzberg AF, Lyons DM.  J Steroid Biochem Mol Biol.  2005; 94 (4): 319-26
• Aging and the role of the HPA axis and rhythm in sleep and memory-consolidation. Buckley TM,  Schatzberg AF.  Am J Geriatr Psychiatry.  2005; 13 (5): 344-52
• Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Schatzberg AF,  Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB.  Arch Gen Psychiatry.  2005; 62 (5): 513-20
• Prospective investigation of stress inoculation in young monkeys. Parker KJ,  Buckmaster CL, Schatzberg AF, Lyons DM.  Arch Gen Psychiatry.  2004; 61 (9): 933-41
• The relationship of chronic pain and depression. Schatzberg AF,  J Clin Psychiatry.  2004; 65 Suppl 12 3-4
• Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. Killen JD,  Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, Samuels D, Levin SK, Green S, Schatzberg AF.  J Consult Clin Psychol.  2004; 72 (4): 729-35
• Cognitive correlates of white matter growth and stress hormones in female squirrel monkey adults. Lyons DM,  Yang C, Eliez S, Reiss AL, Schatzberg AF.  J Neurosci.  2004; 24 (14): 3655-62
• Pharmacologic treatments of major depression: are two mechanisms really better than one? Schatzberg AF,  J Clin Psychiatry.  2004; 65 Suppl 4 3-4
• Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. Fleming SK,  Blasey C, Schatzberg AF.  J Psychiatr Res.  2004; 38 (1): 27-35
• Non-schizophrenic psychoses: common and distinguishing features. Schatzberg AF,  J Psychiatr Res.  2004; 38 (1): 1-2
• Employing pharmacologic treatment of bipolar disorder to greatest effect. Schatzberg AF,  J Clin Psychiatry.  2004; 65 Suppl 15 15-20
• Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Murphy GM,  Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.  Arch Gen Psychiatry.  2004; 61 (11): 1163-9
• Major depression among adolescent smokers undergoing treatment for nicotine dependence. Killen JD,  Robinson TN, Ammerman S, Hayward C, Rogers J, Samuels D, Schatzberg AF.  Addict Behav.  2004; 29 (8): 1517-26
• Functional brain imaging of olfactory processing in monkeys. Boyett-Anderson JM,  Lyons DM, Reiss AL, Schatzberg AF, Menon V.  Neuroimage.  2003; 20 (1): 257-64
• Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Schatzberg AF,  J Clin Psychiatry.  2003; 64 Suppl 13 30-7
• Introduction: treating depression and anxiety to remission. Schatzberg AF,  J Clin Psychiatry.  2003; 64 Suppl 15 3-4
• Pharmacogenetics of antidepressant medication intolerance. Murphy GM,  Kremer C, Rodrigues HE, Schatzberg AF.  Am J Psychiatry.  2003; 160 (10): 1830-5
• The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Murphy GM,  Kremer C, Rodrigues H, Schatzberg AF.  Biol Psychiatry.  2003; 54 (7): 665-73
• Early maternal availability and prefrontal correlates of reward-related memory. Lyons DM,  Schatzberg AF.  Neurobiol Learn Mem.  2003; 80 (2): 97-104
• Onset of major depression during treatment for nicotine dependence. Killen JD,  Fortmann SP, Schatzberg A, Hayward C, Varady A.  Addict Behav.  2003; 28 (3): 461-70
• New approaches to managing psychotic depression. Schatzberg AF,  J Clin Psychiatry.  2003; 64 Suppl 1 19-23
• Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study. Greicius MD,  Krasnow B, Boyett-Anderson JM, Eliez S, Schatzberg AF, Reiss AL, Menon V.  Hippocampus.  2003; 13 (1): 164-74
• Neuroendocrine aspects of hypercortisolism in major depression. Parker KJ,  Schatzberg AF, Lyons DM.  Horm Behav.  2003; 43 (1): 60-6
• A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. DeBattista C,  Solvason HB, Poirier J, Kendrick E, Schatzberg AF.  J Clin Psychopharmacol.  2003; 23 (1): 27-30
• Using chronic pain to predict depressive morbidity in the general population. Ohayon MM,  Schatzberg AF.  Arch Gen Psychiatry.  2003; 60 (1): 39-47
• Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Schatzberg AF,  Kremer C, Rodrigues HE, Murphy GM.  Am J Geriatr Psychiatry.  2002 Sep-Oct; 10 (5): 541-50
• Experience-dependent asymmetric variation in primate prefrontal morphology. Lyons DM,  Afarian H, Schatzberg AF, Sawyer-Glover A, Moseley ME.  Behav Brain Res.  2002; 136 (1): 51-9
• Pharmacological principles of antidepressant efficacy. Schatzberg AF,  Hum Psychopharmacol.  2002; 17 Suppl 1 S17-22
• Prevalence of depressive episodes with psychotic features in the general population. Ohayon MM,  Schatzberg AF.  Am J Psychiatry.  2002; 159 (11): 1855-61
• Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. Lindley SE,  Bengoechea TG, Wong DL, Schatzberg AF.  Brain Res.  2002; 958 (2): 414-22
• Clinical use of nefazodone in major depression: a 6-year perspective. Schatzberg AF,  Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW.  J Clin Psychiatry.  2002; 63 Suppl 1 18-31
• Relating semantic and episodic memory systems. Menon V,  Boyett-Anderson JM, Schatzberg AF, Reiss AL.  Brain Res Cogn Brain Res.  2002; 13 (2): 261-5
• Corticosteroids and cognition. Belanoff JK,  Gross K, Yager A, Schatzberg AF.  J Psychiatr Res.  2001 May-Jun; 35 (3): 127-45
• Early life stress and inherited variation in monkey hippocampal volumes. Lyons DM,  Yang C, Sawyer-Glover AM, Moseley ME, Schatzberg AF.  Arch Gen Psychiatry.  2001; 58 (12): 1145-51
• Rapid detection of the C-1496G polymorphism in the CYP2D6 *2 allele. Claassen JD,  Pascoe N, Schatzberg AF, Murphy GM.  Clin Chem.  2001; 47 (12): 2153-5
• Rapid reversal of psychotic depression using mifepristone. Belanoff JK,  Flores BH, Kalezhan M, Sund B, Schatzberg AF.  J Clin Psychopharmacol.  2001; 21 (5): 516-21
• Cortisol activity and cognitive changes in psychotic major depression. Belanoff JK,  Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF.  Am J Psychiatry.  2001; 158 (10): 1612-6
• Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Chu JW,  Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D.  J Clin Endocrinol Metab.  2001; 86 (8): 3568-73
• Sertraline versus imipramine to prevent relapse in chronic depression. Koran LM,  Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB.  J Affect Disord.  2001; 65 (1): 27-36
• Nicotine patch and paroxetine for smoking cessation. Killen JD,  Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A.  J Consult Clin Psychol.  2000; 68 (5): 883-9
• Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Schatzberg AF,  Kraemer HC.  Biol Psychiatry.  2000; 47 (8): 736-44
• Cognitive-behavioral group therapy for social phobia in female adolescents: results of a pilot study. Hayward C,  Varady S, Albano AM, Thienemann M, Henderson L, Schatzberg AF.  J Am Acad Child Adolesc Psychiatry.  2000; 39 (6): 721-6
• Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey (Saimiri sciureus). Tolwani RJ,  Waggie KS, Green SL, Tolwani AJ, Lyons DM, Schatzberg AF.  J Med Primatol.  2000; 29 (1): 42-5
• Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Schatzberg AF,  Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK.  Am J Psychiatry.  2000; 157 (7): 1095-100
• Clinical efficacy of reboxetine in major depression. Schatzberg AF,  J Clin Psychiatry.  2000; 61 Suppl 10 31-8
• Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. DeBattista C,  Posener JA, Kalehzan BM, Schatzberg AF.  Am J Psychiatry.  2000; 157 (8): 1334-7
• New indications for antidepressants. Schatzberg AF,  J Clin Psychiatry.  2000; 61 Suppl 11 9-17
• Early environmental regulation of glucocorticoid feedback sensitivity in young adult monkeys. Lyons DM,  Yang C, Mobley BW, Nickerson JT, Schatzberg AF.  J Neuroendocrinol.  2000; 12 (8): 723-8
• Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys. Lyons DM,  Lopez JM, Yang C, Schatzberg AF.  J Neurosci.  2000; 20 (20): 7816-21
• Postnatal experiences and genetic effects on squirrel monkey social affinities and emotional distress. Lyons DM,  Martel FL, Levine S, Risch NJ, Schatzberg AF.  Horm Behav.  1999; 36 (3): 266-75
• Salivary cortisol levels in socially phobic adolescent girls. Martel FL,  Hayward C, Lyons DM, Sanborn K, Varady S, Schatzberg AF.  Depress Anxiety.  1999; 10 (1): 25-7
• Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Lindley SE,  Bengoechea TG, Schatzberg AF, Wong DL.  Neuropsychopharmacology.  1999; 21 (3): 399-407
• Phenomenology and treatment of agitation. Schatzberg AF,  DeBattista C.  J Clin Psychiatry.  1999; 60 Suppl 15 17-20
• Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. Lindley SE,  Bengoechea TG, Wong DL, Schatzberg AF.  Brain Res.  1999; 832 (1-2): 152-8
• Separation induced changes in squirrel monkey hypothalamic-pituitary-adrenal physiology resemble aspects of hypercortisolism in humans. Lyons DM,  Wang OJ, Lindley SE, Levine S, Kalin NH, Schatzberg AF.  Psychoneuroendocrinology.  1999; 24 (2): 131-42
• Antidepressant effectiveness in severe depression and melancholia. Schatzberg AF,  J Clin Psychiatry.  1999; 60 Suppl 4 14-21; discussion 22
• McLean Hospital depression research facility: early-onset phobic disorders and adult-onset major depression. Schatzberg AF,  Samson JA, Rothschild AJ, Bond TC, Regier DA.  Br J Psychiatry Suppl.  1998; (34): 29-34
• Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Schatzberg AF,  J Clin Psychiatry.  1998; 59 Suppl 14 15-8
• Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. DeBattista C,  Sofuoglu M, Schatzberg AF.  Biol Psychiatry.  1998; 44 (5): 341-7
• Bipolar disorder: recent issues in diagnosis and classification. Schatzberg AF,  J Clin Psychiatry.  1998; 59 Suppl 6 5-10; discussion 11-2
• Postnatal foraging demands alter adrenocortical activity and psychosocial development. Lyons DM,  Kim S, Schatzberg AF, Levine S.  Dev Psychobiol.  1998; 32 (4): 285-91
• The dynamics of sex: gender differences in psychiatric disorders. Schatzberg AF,  J Clin Psychiatry.  1997; 58 Suppl 15 3-4
• Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. Schatzberg AF,  Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J.  J Clin Psychiatry.  1997; 58 Suppl 7 23-7
• Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. Schatzberg AF,  Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J.  J Clin Psychiatry.  1997; 58 Suppl 7 5-10
• Treatment of severe depression with the selective serotonin reuptake inhibitors. Schatzberg AF,  Depress Anxiety.  1996-1997; 4 (4): 182-9
• Serotonin activity in psychotic (delusional) major depression. Schatzberg AF,  Rothschild AJ.  J Clin Psychiatry.  1992; 53 Suppl 52-5